Open AccessIn Vitro and In Vivo Activities of a Novel Cephalosporin, BMS-247243, against Organisms other than Staphylococci
Author(s) -
Junius M. Clark,
J Fung-Tomc,
Beatrice Minassian,
Yuan-Hwang Tsai,
Hyekyung Yang,
E Huczko,
B Kolek,
Susan Chaniewski,
Cheryl Ferraro,
Rebecca L. Drain,
Elizabeth Gradelski,
D P Bonner
Publication year - 2002
Publication title -
antimicrobial agents and chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.07
H-Index - 259
eISSN - 1070-6283
pISSN - 0066-4804
DOI - 10.1128/aac.46.4.1108-1111.2002
Subject(s) - microbiology and biotechnology , cefotaxime , enterococcus faecalis , cephalosporin , enterococcus faecium , streptococcus pneumoniae , enterococcus , anaerobic bacteria , vancomycin , biology , bacteria , antibiotics , staphylococcus aureus , genetics
BMS-247243, a novel cephalosporin inhibitory for methicillin-resistant staphylococci, primarily has activity against gram-positive bacteria. The activities of BMS-247243, cefotaxime, and ceftriaxone against streptococci and Streptococcus pneumoniae were similar. BMS-247243 inhibits Enterococcus faecalis but not Enterococcus faecium. BMS-247243 also inhibits many inherently vancomycin-resistant species (Leuconstoc, Lactobacillus, Pediococcus) and anaerobic gram-positive bacteria.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom